Search global stocks & ETFs...Ctrl K
Learn Mode
EXEL
Stock Profile
07-27
Recommended Metric
Score Card
Explore Scores Tab
4.07
Good
Valuation Score
Key Score
3.00
Average
Management
1.00
Very Bad
Growth
2.00
Bad
Profitability
5.00
Very Good
Fin. Health
2.00
Bad
Dividends
--
--
Analyst
4.00
Good
Insider Transactions
Explore Insider Tab ›Buy Transactions
Sell Transactions
Peers
Select stocks to compare
Price Targets & Ratings
View Analysis
1-year price targets, ending May 11, 2027
Current
$53.96
Baseline
High
$63.00
▲
16.75%
Avg
$50.04
▼
-7.26%
Low
$40.40
▼
-25.13%
Analyst Ratings based on 26 Analysts
Strong Buy
623%
Buy
935%
Hold
1038%
Sell
104%
Strong Sell
000%
Exelixis, Inc. is an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. The company is headquartered in Alameda, California and currently employs 1,077 full-time employees. The company went IPO on 2000-04-11. The firm has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. The company is also advancing and evolving its product pipeline portfolio, including its lead investigational asset, zanzalintinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma, for previously treated hepatocellular carcinoma and for previously treated, radioactive iodine-refractory differentiated thyroid cancer, and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer. The firm's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved the treatment of hypertension in Japan.Read More